logo
title

Riccardo  Dalla-Favera
Riccardo Dalla-Favera
Professor & Director, Institute for Cancer Genetics
Uris Professor of Pathology


Address: 1130 St. Nicholas Avenue Irving Comprehensive Research Center, ICRC Room 508A New York NY 10032
Phone: 212-851-5273
Fax: 212-851-5256
E-mail:

rd10@columbia.edu

Education and Training:
M.D. 1976, University of Milan
Affiliations:
bullet  Institute for Cancer Genetics
bullet  Department of Genetics and Development
Training Activities:
Research Summary:
(800 words, max)
Molecular genetics of cancer; molecular pathogenesis of lymphoma and leukemia; genetic control in lymphoid tissue development.
Current Research:
The general goal of this laboratory is to elucidate the pathogenesis of cancers derived from B lymphocytes, known as B cell lymphomas. These tumors originate from the malignant transformation of germinal center B cells, via acquisition of genomic lesions involving oncogenes and tumor suppressor genes. We wish to identify these lesions, determine the mechanism by which they occur and elucidate the contribution of each lesion to tumor development using genetically modified mouse models. These studies are also aimed at identifying targets for therapeutic intervention. Specific lines of investigation include:

1) Integrate genome-wide genomic and transcriptomic analyses to identify the genetic lesions involved in the development of Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (CLL), the two most common forms of B cell malignancies.

2) Elucidate the physiologic role of the genes altered in DLBCL and CLL by identifying their function in germinal center development through the combination of biochemical and functional assays as well as genetically engineered mice with specific gene deletion in germinal center B cells.

3) Identify the pathologic role of DLBCL- and CLL-associated genetic lesions by recapitulating them in the germinal center of mice.

4) Test novel therapeutic approaches for their ability to target newly discovered genetic lesions and cellular pathways altered in tumors.
Publications:
(6 max)
1. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L.H., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., V., Murty, V.V., Mullighan, C.G., Gaidano, G., Rabadan, R., Brindle, P.K., Dalla-Favera, R.: (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma.  Nature  471: 189-195

2. Pasqualucci, L. Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V.A., Grunn, A., Messina, M., Elliot, O., Chan, J., Bhagat, G., Chadburn, A., Gaidano, G., Mullighan, C. G., Rabadan, R., and Dalla-Favera, R.: (2011) Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma.  Nature Genetics  43(9): 830-837

3. Challa-Malladi, M., Lieu, Y.K., Califano, O., Holmes, A., Bhagat, G., Dominguez-Sola, D., Murty, V.V., Pasqualucci, L., Dalla-Favera, R.: (2011) Combined Genetic Inactivation of Beta2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B-cell Lymphoma.  Cancer Cell  13:20(6): 728-740

4. Dominguez-Sola, D., Victora, G.D., Ying, C.Y., Phan, R.T., Saito, M., Nussenzweig, M.C., Dalla-Favera, R.: (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry.  Nat Immunology  13(11): 1083-1091

5. Ying, C.Y., Dominguez-Sola, D., Fabi, M., Lorenz, I.C., Hussein, S., Bansal, M., Califano, A., Pasqualucci, L., Basso, K., Dalla-Favera, R.: (2013) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in diffuse large B cell lymphoma.  Nature Immunology  10: 1084-1092

6. Pasqualucci, L., Khiabanian, H., Fangazio, M., Vasishtha, M., Messina, M., Holmes, A.B., Ouillette, P., Trifonov, V., Rossi, D., Tabḅ, F., Ponzoni, M., Chadburn, A., Murty, V.V., Bhagat, G., Gaidano, G., Inghirami, G., Malek, S.N., Rabadan, R., Dalla-Fav: (2014) Genetics of Follicular Lymphoma Transformation.  Cell Reports  16;6(1): 130-140

URL for lab page:
 

top

footer